216 related articles for article (PubMed ID: 35201950)
1. Vogt-Koyanagi-Harada Relapse after COVID-19 Vaccination.
Accorinti M; Saturno MC; Manni P
Ocul Immunol Inflamm; 2022 Jul; 30(5):1228-1233. PubMed ID: 35201950
[TBL] [Abstract][Full Text] [Related]
2. Vogt-Koyanagi-Harada Disease Exacerbation Associated with COVID-19 Vaccine.
De Domingo B; López M; Lopez-Valladares M; Ortegon-Aguilar E; Sopeña-Perez-Argüelles B; Gonzalez F
Cells; 2022 Mar; 11(6):. PubMed ID: 35326462
[TBL] [Abstract][Full Text] [Related]
3. Reactivation of previously controlled Vogt-Koyanagi-Harada disease more than 46 years following COVID-19 vaccination: a case study.
Muto T; Sakamoto M; Imaizumi S; Kamoi K
J Int Med Res; 2024 Jan; 52(1):3000605231221081. PubMed ID: 38170955
[TBL] [Abstract][Full Text] [Related]
4. Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease.
Xu K; Gao B; Li J; Xiang Y; Cao L; Zhao M
Hum Vaccin Immunother; 2023 Aug; 19(2):2220630. PubMed ID: 37282614
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 Developed During Systemic Steroid Therapy for Vogt-Koyanagi-Harada Disease: A Case Report.
Niidome S; Usui Y; Tsubota K; Sugawara R; Goto H
Ocul Immunol Inflamm; 2023 Aug; 31(6):1305-1309. PubMed ID: 37084286
[TBL] [Abstract][Full Text] [Related]
6. Vogt-Koyanagi-Harada Disease following mRNA-1273 (Moderna) COVID-19 Vaccination.
Joo CW; Kim YK; Park SP
Ocul Immunol Inflamm; 2022 Jul; 30(5):1250-1254. PubMed ID: 35404752
[TBL] [Abstract][Full Text] [Related]
7. A COVID-19 perspective of Vogt-Koyanagi-Harada disease.
Dutta Majumder P; Sadhu S; González-López JJ; Mochizuki M
Indian J Ophthalmol; 2023 Jun; 71(6):2587-2591. PubMed ID: 37322685
[TBL] [Abstract][Full Text] [Related]
8. Multicenter, retrospective, observational study for the Treatment Pattern of systemic corticoSTERoids for relapse of non-infectious uveitis accompanying Vogt-Koyanagi-Harada disease or sarcoidosis.
Namba K; Takase H; Usui Y; Nitta F; Maruyama K; Kusuhara S; Takeuchi M; Azumi A; Yanai R; Kaneko Y; Hasegawa E; Nakai K; Tsuruga H; Morita K; Kaburaki T
Jpn J Ophthalmol; 2022 Mar; 66(2):130-141. PubMed ID: 35044561
[TBL] [Abstract][Full Text] [Related]
9. [Long-term course of immunosuppressive therapy of Vogt-Koyanagi-Harada syndrome].
Wand K; Abraham S; Loos D; Stumpfe S; Lohmann C; Maier M; Feucht N
Ophthalmologe; 2015 Oct; 112(10):857-60. PubMed ID: 25680347
[TBL] [Abstract][Full Text] [Related]
10. Vogt-Koyanagi-Harada disease after SARS-CoV-2 infection: Case report and literature review.
Zou H; Zhang K; Chen X; Sha S
Immun Inflamm Dis; 2024 Apr; 12(4):e1250. PubMed ID: 38661242
[TBL] [Abstract][Full Text] [Related]
11. The use of low-dose azathioprine in patients with Vogt-Koyanagi-Harada disease.
Kim SJ; Yu HG
Ocul Immunol Inflamm; 2007; 15(5):381-7. PubMed ID: 17972222
[TBL] [Abstract][Full Text] [Related]
12. Acute phase clinical manifestations of patients with Vogt-Koyanagi-Harada disease in Southern China.
Zhang C; Wang Y; Chen Y; Zhou H; Hong Q; Yu X; Ng TK; Cen LP
BMC Ophthalmol; 2023 May; 23(1):199. PubMed ID: 37147563
[TBL] [Abstract][Full Text] [Related]
13. Catching the therapeutic window of opportunity in early initial-onset Vogt-Koyanagi-Harada uveitis can cure the disease.
Herbort CP; Abu El Asrar AM; Takeuchi M; Pavésio CE; Couto C; Hedayatfar A; Maruyama K; Rao X; Silpa-Archa S; Somkijrungroj T
Int Ophthalmol; 2019 Jun; 39(6):1419-1425. PubMed ID: 29948499
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporin therapy in Vogt Koyanagi Harada disease.
Wakefield D; McCluskey P; Reece G
Aust N Z J Ophthalmol; 1990 May; 18(2):137-42. PubMed ID: 2390240
[TBL] [Abstract][Full Text] [Related]
15. Case with metastatic cutaneous malignant melanoma that developed Vogt-Koyanagi-Harada-like uveitis following pembrolizumab treatment.
Enomoto H; Kato K; Sugawara A; Itabashi M; Kondo M
Doc Ophthalmol; 2021 Jun; 142(3):353-360. PubMed ID: 33392895
[TBL] [Abstract][Full Text] [Related]
16. Possible Association between Vogt-Koyanagi-Harada Disease and Coronavirus Disease Vaccine: A Report of Four Cases.
de Queiroz Tavares Ferreira F; Araújo DC; de Albuquerque LM; Bianchini PM; Holanda EC; Pugliesi A
Ocul Immunol Inflamm; 2023 Aug; 31(6):1134-1140. PubMed ID: 35914285
[TBL] [Abstract][Full Text] [Related]
17. Systemic corticosteroid treatment in Vogt-Koyanagi-Harada disease.
Hayasaka S; Okabe H; Takahashi J
Graefes Arch Clin Exp Ophthalmol; 1982; 218(1):9-13. PubMed ID: 7056483
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
[TBL] [Abstract][Full Text] [Related]
19. Vogt-Koyanagi-Harada disease following ChAdOx1 nCoV-19 and mRNA-1273 vaccination.
Rujkorakarn P; Patamatamkul S
J Fr Ophtalmol; 2023 Mar; 46(3):207-210. PubMed ID: 36775731
[TBL] [Abstract][Full Text] [Related]
20. [Vogt-Koyanagi-Harada syndrome in children].
Laghmari M; Karim A; Ibrahimy W; Essakalli NH; Mohcine Z
J Fr Ophtalmol; 2002 Jun; 25(6):636-40. PubMed ID: 12223954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]